Bristol-Myers Squibb reported another strong quarter which happened to be an all-around beat. Its revenue growth was largely driven by its new product and in-line portfolios. The company also made progress in advancing its pipeline. This includes the launch of three new first-in-class medicines as well as the progress of six promising programs in the registrational development. The sales of Global Opdivo reflect robust demand for its newly launched and also a core indication of double-digit grow ....
